The U.S. Food and Drug Administration has granted marketing authorization to ipsogen JAK2 RGQ PCR Kit, manufactured by QIAGEN GmbH., to detect mutations affecting the Janus Tyrosine Kinase 2 (JAK2) gene. This is the first FDA-authorized test intended to help physicians in evaluating patients for suspected Polycythemia Vera (PV).
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO has announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017-2018 ASCO Health Policy Fellowship program, now entering its second year.
On April 5, ASCO announced that Instituto de Oncologia do Vale (IOV) has become the first practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program, LLC. IOV is the second international practice to achieve this milestone in demonstrating the quality of care it provides to oncology patients.
On Friday, March 24, the U.S. House of Representatives withdrew H.R. 1628, the "American Health Care Act" (AHCA), which would have repealed and partly replaced the Affordable Care Act (ACA). House Members were unable to come to an agreement on enough key details to pass the bill.
CancerLinQ, LLC CEO, Kevin Fitzpatrick will join leaders of the cancer community including the Cancer Support Community and the American Cancer Society in speaking at the 2017 eyeforpharma Oncology Market Access & Pricing, taking place in Philadelphia.
Lawmakers expressed their concerns with proposed cuts to the National Institutes of Health (NIH) during hearings on Capitol Hill.
In a position statement released today, the American Society of Clinical Oncology (ASCO) stated its strong support for increasing access to investigational new treatment options for patients with cancer, while raising serious concerns about recently proposed federal "right-to-try" (RTT) legislation as well as enacted state RTT laws. ASCO said these measures lack adequate patient protections and do not remove any of the major barriers patients face in accessing investigational drugs outside of clinical trials.
On April 1, Jack F. Whelan, a member of the CancerLinQ® Patient Advisory Committee, received an award from the American Association for Cancer Research for his history of advocacy on behalf of patients with cancer and their family and friends.
Members of ASCO's Leadership Development program participated in a Hill Day to advocate for key cancer policy priorities.
A recent study, “Insurance denials for cancer clinical trial participation after the Affordable Care Act (ACA) mandate”, published in Cancer found that real or perceived lack of coverage of routine cost of cancer clinical trials persist following the passage of the ACA. The authors conclude that these persisting coverage denials and delays remain a substantial barrier to patient participation in cancer clinical trials.
On April 3, 2017, ASCO issued recommendations addressing the needs of sexual and gender minority populations as they relate to cancer.
On March 31, 2017, the U.S. Food and Drug Administration granted regular approval to palbociclib (IBRANCE®, Pfizer Inc.) for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women.
The American Society of Clinical Oncology (ASCO) has released a set of recommendations to enhance the role of observational cancer research in clinical decision-making. Published in the Journal of Clinical Oncology (JCO), the ASCO research statement discusses the expanding opportunities to utilize observational studies to advance cancer research and supplement the knowledge gained through cancer clinical trials.
On March 30, 2017, the U.S. Food and Drug Administration granted regular approval to osimertinib (TAGRISSO® , AstraZeneca Pharmaceuticals, LP) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
CancerLinQ LLC is partnering with the leading association for hematology/oncology pharmacy professionals, the Hematology/Oncology Pharmacy Association (HOPA).